Buchumschlag

Afatinib alone or afatinib plus vinorelbine versus investigator’s choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Cortes, Javier (VerfasserIn) , Schneeweiss, Andreas (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: December 2015
In: The lancet. Oncology
Year: 2015, Jahrgang: 16, Heft: 16, Pages: 1700-1710
ISSN:1474-5488
DOI:10.1016/S1470-2045(15)00373-3
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1016/S1470-2045(15)00373-3
Volltext
Verfasserangaben:Javier Cortés, Véronique Dieras, Jungsil Ro, Jérôme Barriere, Thomas Bachelot, Sara Hurvitz, Emilie Le Rhun, Marc Espié, Sung-Bae Kim, Andreas Schneeweiss, Joo Hyuk Sohn, Jean-Marc Nabholtz, Pirkko-Liisa Kellokumpu-Lehtinen, Julie Taguchi, Federico Piacentini, Eva Ciruelos, Petri Bono, Mahmoud Ould-Kaci, Flavien Roux, Heikki Joensuu

MARC

LEADER 00000caa a2200000 c 4500
001 1545587930
003 DE-627
005 20220813025605.0
007 cr uuu---uuuuu
008 160801s2015 xx |||||o 00| ||eng c
024 7 |a 10.1016/S1470-2045(15)00373-3  |2 doi 
035 |a (DE-627)1545587930 
035 |a (DE-576)475587936 
035 |a (DE-599)BSZ475587936 
035 |a (OCoLC)1340926699 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Cortes, Javier  |e VerfasserIn  |0 (DE-588)142653705  |0 (DE-627)638445590  |0 (DE-576)332633640  |4 aut 
245 1 0 |a Afatinib alone or afatinib plus vinorelbine versus investigator’s choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3)  |b a randomised, open-label, multicentre, phase 2 trial  |c Javier Cortés, Véronique Dieras, Jungsil Ro, Jérôme Barriere, Thomas Bachelot, Sara Hurvitz, Emilie Le Rhun, Marc Espié, Sung-Bae Kim, Andreas Schneeweiss, Joo Hyuk Sohn, Jean-Marc Nabholtz, Pirkko-Liisa Kellokumpu-Lehtinen, Julie Taguchi, Federico Piacentini, Eva Ciruelos, Petri Bono, Mahmoud Ould-Kaci, Flavien Roux, Heikki Joensuu 
264 1 |c December 2015 
300 |a 11 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 01.08.2016 
700 1 |a Schneeweiss, Andreas  |d 1961-  |e VerfasserIn  |0 (DE-588)109972554  |0 (DE-627)632849630  |0 (DE-576)327251859  |4 aut 
773 0 8 |i Enthalten in  |t The lancet. Oncology  |d London : The Lancet Publ. Group, 2000  |g 16(2015), 16, Seite 1700-1710  |h Online-Ressource  |w (DE-627)325349770  |w (DE-600)2035574-9  |w (DE-576)100517544  |x 1474-5488  |7 nnas  |a Afatinib alone or afatinib plus vinorelbine versus investigator’s choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3) a randomised, open-label, multicentre, phase 2 trial 
773 1 8 |g volume:16  |g year:2015  |g number:16  |g pages:1700-1710  |g extent:11  |a Afatinib alone or afatinib plus vinorelbine versus investigator’s choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3) a randomised, open-label, multicentre, phase 2 trial 
856 4 0 |u http://dx.doi.org/10.1016/S1470-2045(15)00373-3  |x Verlag  |x Resolving-System  |3 Volltext 
951 |a AR 
992 |a 20160801 
993 |a Article 
994 |a 2015 
998 |g 109972554  |a Schneeweiss, Andreas  |m 109972554:Schneeweiss, Andreas  |d 910000  |e 910000PS109972554  |k 0/910000/  |p 10 
999 |a KXP-PPN1545587930  |e 2935585720 
BIB |a Y 
SER |a journal 
JSO |a {"origin":[{"dateIssuedDisp":"December 2015","dateIssuedKey":"2015"}],"physDesc":[{"extent":"11 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"name":{"displayForm":["Javier Cortés, Véronique Dieras, Jungsil Ro, Jérôme Barriere, Thomas Bachelot, Sara Hurvitz, Emilie Le Rhun, Marc Espié, Sung-Bae Kim, Andreas Schneeweiss, Joo Hyuk Sohn, Jean-Marc Nabholtz, Pirkko-Liisa Kellokumpu-Lehtinen, Julie Taguchi, Federico Piacentini, Eva Ciruelos, Petri Bono, Mahmoud Ould-Kaci, Flavien Roux, Heikki Joensuu"]},"id":{"doi":["10.1016/S1470-2045(15)00373-3"],"eki":["1545587930"]},"person":[{"role":"aut","given":"Javier","display":"Cortes, Javier","family":"Cortes"},{"display":"Schneeweiss, Andreas","family":"Schneeweiss","role":"aut","given":"Andreas"}],"recId":"1545587930","relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"id":{"zdb":["2035574-9"],"eki":["325349770"],"issn":["1474-5488"]},"origin":[{"publisherPlace":"London","dateIssuedKey":"2000","publisher":"The Lancet Publ. Group","dateIssuedDisp":"2000-"}],"recId":"325349770","pubHistory":["0.2000 -"],"language":["eng"],"note":["Gesehen am 22.09.2021"],"title":[{"title_sort":"lancet","partname":"Oncology","title":"The lancet"}],"disp":"Afatinib alone or afatinib plus vinorelbine versus investigator’s choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3) a randomised, open-label, multicentre, phase 2 trialThe lancet. Oncology","part":{"volume":"16","text":"16(2015), 16, Seite 1700-1710","issue":"16","extent":"11","pages":"1700-1710","year":"2015"},"titleAlt":[{"title":"The lancet <London> / Oncology"}]}],"title":[{"title":"Afatinib alone or afatinib plus vinorelbine versus investigator’s choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3)","subtitle":"a randomised, open-label, multicentre, phase 2 trial","title_sort":"Afatinib alone or afatinib plus vinorelbine versus investigator’s choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3)"}],"note":["Gesehen am 01.08.2016"],"language":["eng"]} 
SRT |a CORTESJAVIAFATINIBAL2015 

Ähnliche Einträge